Changes in PROs can predict disease flares among patients with RA who discontinued csDMARD therapy after achieving sustained remission.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

A study of more than 100 patients found that immunotherapy can cure a rare type of cancer in various tumor sites without ...

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

In April 2025, Terns enrolled the first patient in the dose expansion portion of the Phase 1 CARDINAL study of TERN-701 for CML. Patients will be randomized to one of two dose cohorts (320 mg or 500 ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...